Here's what I wrote in my first posting when I started this blog a year ago today: Medical ethics has traditionally focused on the indi...

Here's what I wrote in my first posting when I started this blog a year ago today: Medical ethics has traditionally focused on the indi...
India is developing drug trials as a budding industrial sector. It is predicted that trials outsourced from the U.S. and Europe will bring $...
Charlie Baker, CEO at Harvard Pilgrim Health Care, where I direct the ethics program, has a valuable posting about "Bending the Health...
Good news! Harry and Louise are back. And they've changed a lot since they deep-sixed the Clinton health plan in 1994. Their big concern...
In Act V of Romeo and Juliet , Romeo, heartbroken by his (mistaken) belief that Juliet is dead, offers an apothecary 40 ducats for "a d...
Two years ago, West Virginia launched a Medicaid redesign based on the premise that beneficiaries should be expected to play an active role ...
Three days ago I criticized PhRMA's heavy-handed attack on the relatively mild restrictions Massachusetts Senate Bill 2863 imposes on d...
Today's Daily Telegraph ( here and here ) bitterly attacks NICE (the National Institute for Health and Clinical Excellence) for not ado...
Yesterday Massachusetts Governal Deval Patrick signed Senate Bill 2863 , "An Act to promote Cost Containment, Transparency and Efficien...
On reason "ethics" has a bad name is the gap between espoused principles and the behavior of individuals and organizations. Highfa...
In organizational and health system ethics, the public is a key stakeholder. I've thought for a long time that widely held public values...
After I wrote yesterday's post about refugees and asylum seekers in the British National Health Service, I read a remarkable article in...
In January I wrote ( here ) about GP resistance to a proposed National Health Service directive that they not treat asylum seekers or undocu...